A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
445actual
Sites
49
Countries
Australia, Canada, Mexico +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-01 | actual | When the study began enrolling |
| Primary completion | 2025-11-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-14 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
- Osteo Arthritis Knee
Interventions
- Drug: Retatrutide — also filed as LY3437943
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
measured Baseline, Week 68
Percent Change from Baseline in Body Weight
measured Baseline, Week 68
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed